An FDA Reversal on Peptides Could Open the Market to Unsafe Drugs ProPublica FDA to weigh easing limits on unproven peptides favored by RFK Jr. and other MAHA figures Pittsburgh Post Gazette FDA moves toward easing restrictions on certain peptides BioPharma Dive The Peptide Moment: How FDA's Regulatory Reversal Creates Risk and Opportunity for Venture Capital and Private Equity Guidepost Solutions Gray Market Peptides: So Much Hype, So Little Data The Hidden Risks of BPC157: What Patients Need to Know About Contamination and Safety Regenexx at New Regeneration Orthopedics